the aid library

LIST OPTIONS

Download (308)

View PDF (523)

Planning for country transition to Xpert MTB/RIF Ultra Cartridges

Global Laboratory Initiative (2017) C2

External Link

Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?

D. C. Etal Agora Research Letter (2017) C2

Eur Respir J 2017; 50: 1700918

Download (225)

View PDF (440)

Considerations for adoption and use of multidisease testing devices in integrated laboratory networks

World Health Organization (2017) C_WHO

Information note.
This information note provides a strategic overview of key implementation considerations for diagnostic integration using these devices, and is primarily intended for use by national laboratory services and TB, HIV, and hepatitis programme managers.
It may also be of inte... more

Download (1902)

View PDF (2829)

Botswana Essential Drug List (BEDL)

Botswana Essential Drug Action Programme (BEDAP), Ministry of Health, Republic of Botswana (2012) C2

Second Edition, 2012

Download (115)

View PDF (185)

WHO list of prequalified in vitro diagnostic products

World Health Organization (2017) C_WHO

Target Product Profile for Zaïre ebolavirus rapid, simple test to be used in the control of the Ebola outbreak in West Africa

World Health Organization (2014) CC3

Download (450)

View PDF (722)

Impact of Point-of-Care EID Testing into the National EID Program: Pilot Experiences from Malawi

International AIDS conference Durban, South Africa; Ministry of Health, Malawi; (2016) C1

Download (884)

View PDF (1777)

Tuberculosis. Diagnostics Technology Landscape. 5th edition
recommended

UNITAID World Health Organisation (WHO) (2017) C2

Download (287)

View PDF (565)

INDEX-TB GUIDELINES: Evidence Summaries and Guideline Panel Decision Tables Core Group Guideline Meeting

(2016) C1

This document contains: The systematic reviews and GRADE assessments used at the Index-TB Guideline Panel in July 2015; The Evidence to Decision tables that record the Panel’s assessment and recommendations from this meeting

External Link

List of Priority Medical Devices for COVID-19 Case Management
recommended

World Health Organization WHO (2020) C1

This document is updated. Please check the document:Priority medical devices list for the COVID-19 response and associated technical specifications

Medical Waste Management in Developing Countries

Zafar, S. Vivis (2019) C1

Report on the Review of the Kenya National Guidelines for Safe Management of Health Care Waste

UNDP (2018) CC

Injection Safety and Safe Disposal of Medical Waste National Communication Strategy and Health Care Waste Management Standard Operating Procedures (SOPs). The overall objective of the consultancy was to review and align the three national technical and communication guiding documents on HCWM to th... more

Download (200)

View PDF (327)

Waste Management and Recycling Site Visit Questionnaire

Action contre la Faim France; Logistics Cluster (2023) CC

This document complements the WREC Waste Management and Recycling Assessment Guidance and can be used by humanitarian partners to assess waste management and recycling facilities through site visits. It is complemented by an Annex listing hazardous and non-hazardous waste types.

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more